Autopsy report · NCT06241573
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
Cause of deathNo reason given
Life of this trial
- Registered 3 months before it started.
- Ran for about 11 months before it stopped.
- 39 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Spesolimab; Placebo
- Participants
- 39
- Sites
- 36
- Countries
- Argentina, Australia, Bulgaria, Canada, France, Germany, Japan, Lithuania, Malaysia, Poland, Singapore, South Korea and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.